Jinhua Marine Biological (OTCMKTS:JNMB – Get Free Report) and MediWound (NASDAQ:MDWD – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.
Earnings and Valuation
This table compares Jinhua Marine Biological and MediWound’s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Jinhua Marine Biological | N/A | N/A | N/A | N/A | N/A |
MediWound | $20.14 million | 8.84 | -$6.72 million | ($1.38) | -13.89 |
Jinhua Marine Biological has higher earnings, but lower revenue than MediWound.
Institutional and Insider Ownership
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Jinhua Marine Biological and MediWound, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Jinhua Marine Biological | 0 | 0 | 0 | 0 | N/A |
MediWound | 0 | 0 | 2 | 0 | 3.00 |
MediWound has a consensus target price of $29.00, suggesting a potential upside of 51.28%. Given MediWound’s higher probable upside, analysts clearly believe MediWound is more favorable than Jinhua Marine Biological.
Profitability
This table compares Jinhua Marine Biological and MediWound’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Jinhua Marine Biological | N/A | N/A | N/A |
MediWound | -64.24% | -21.67% | -10.23% |
Summary
MediWound beats Jinhua Marine Biological on 5 of the 8 factors compared between the two stocks.
About Jinhua Marine Biological
Jinhua Marine Biological (USA), Inc. develops allopelagic materials, biological medicines, pesticides, environmental protection products, and products for the home. It offers health products, including Xiduoan, which is used for strengthening and adjusting the immune system. The company also introduces advanced wastewater treatment technology, as well as develops environmental protection projects, including industry/urban wastewater treatment. This business was pursued in three areas: the development, manufacture, distribution and sale of ERGOS Systems directly by the Company; consulting services, and the delivery of marketing and other services to ERGOS network providers.
About MediWound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Receive News & Ratings for Jinhua Marine Biological Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jinhua Marine Biological and related companies with MarketBeat.com's FREE daily email newsletter.